Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 12, 2020 / 01:45PM GMT
Release Date Price: $33.58 (-1.96%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Hey, everybody. Good morning. I'm Marty Auster. I'm one of the Smid Cap Biotech analysts here at Crédit Suisse. Thanks for joining us this morning at the 29th Annual Crédit Suisse Healthcare Conference. I'm pleased to be joined right now by Dr. Steve Pakola, Chief Medical Officer of REGENXBIO, who's going to kind of present REGENX story. Thank you very much for joining us this morning. Steve, good to see you. I'll hand it over to you now.

Stephen Pakola
REGENXBIO Inc. - Chief Medical Officer

Hey, Marty, good to see as well this morning. And thanks for the opportunity for us to present. So REGENXBIO, we are a leader in AAV gene therapy treatment. You can advance to our forward-looking statements. So our company, our mission is to improve lives through the curative potential of gene therapy. And we're excited to have the opportunity to do that due to our NAV Technology Platform, which has allowed us to advance into multiple ongoing clinical step

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot